South Africa SAHPRA Pharmaceutical Import: A 2026 Guide for UK Exporters

South Africa is the most developed pharmaceutical market in sub-Saharan Africa, and its hospital sector is unusually diverse. A large public system runs through the National Department of Health and the provincial depots, while three major private groups, of the Netcare, Mediclinic and Life Healthcare type, run their own procurement. Both sides rely on imported originator and specialty medicines for cases their local supply cannot cover. For a hospital pharmacist in Johannesburg or Cape Town, a Department of Health procurement officer, an NGO running a treatment programme, or a licensed distributor, the practical question is usually the same: how do you bring in a UK-licensed medicine in a way the regulator will accept, on a timeline that works for the patient.

That process runs through one authority: the South African Health Products Regulatory Authority, known as SAHPRA. This guide explains how SAHPRA works, the routes a UK-licensed medicine can take into South Africa, the documentation involved, and how supply from an MHRA-licensed UK wholesale exporter fits the pathway in 2026. It is written for the buyer side, the people in South Africa sourcing UK-licensed product, rather than for regulatory consultants.

One point to set out plainly at the start. Euro Biom is a UK MHRA-licensed wholesale exporter supplying UK-licensed, MHRA-authorised finished medicines. We do not manufacture, and we are not a regulatory consultancy. Where this guide describes registration and Section 21 mechanics, those are the buyer's and local applicant's responsibilities in South Africa. Our role is the UK supply leg and the documentation that supports it.

What SAHPRA Is and What It Controls

The South African Health Products Regulatory Authority is the national regulator for medicines, medical devices and in-vitro diagnostics. It was established under the Medicines and Related Substances Act, Act 101 of 1965 as amended, and began operations in 2018 in place of the former Medicines Control Council. It operates as a public entity accountable to the Minister of Health.

Within the pharmaceutical remit, SAHPRA is responsible for the registration of medicines, the licensing and inspection of manufacturers, wholesalers, importers and distributors, Good Manufacturing Practice assessment, import and export permits, clinical trial authorisation, pharmacovigilance and market surveillance.

Several features of SAHPRA matter for a UK exporter and a South African buyer:

• It follows a structure aligned with international practice. SAHPRA reviews dossiers in the Common Technical Document (CTD) format and references ICH guidelines. This helps UK-licensed product, because a medicine carrying MHRA documentation, evidence of approval, GMP evidence and full batch records maps closely onto the format SAHPRA expects.
• It operates reliance and recognition pathways. To manage its workload and reduce historic registration backlogs, SAHPRA has adopted reliance approaches that draw on assessments already carried out by recognised regulators. A product authorised by a stringent authority such as the MHRA therefore starts from a recognised position rather than a standing start.
• GMP sits at the centre of the process. SAHPRA places strong weight on Good Manufacturing Practice for the manufacturing site, and a GMP assessment, whether by on-site inspection or by acceptance of equivalent evidence, is a key gate in the pathway. A UK manufacturing site already operating under MHRA GMP oversight starts from a recognised position.

For the country-level overview of how Euro Biom supplies this market, see our UK pharmaceutical supplier to South Africa page, and for how South Africa sits alongside neighbouring regulators see the regulator comparison tool.

Registration Routes into South Africa

A UK-licensed medicine generally reaches a South African hospital or patient by one of two broad routes. Choosing correctly at the outset saves months.

1. Full SAHPRA registration

This is the route for any product supplied routinely and at volume. A locally established applicant, the holder of the certificate of registration, submits a CTD dossier to SAHPRA. The agency reviews the quality, safety and efficacy documentation, assesses GMP for the manufacturing site, and, where the product has already been evaluated by a recognised authority, may apply its reliance pathway to streamline the review before granting a certificate of registration. Registration is what allows a product to be tendered, stocked and dispensed across the market on an ongoing basis, in both public and private channels.

2. Section 21 access (for an unregistered or unavailable medicine)

Where a medicine is not registered in South Africa, or is registered but not currently available, it can still be brought in through the Section 21 access route. This is the route most relevant to specialty, oncology and rare-disease cases where no registered local equivalent exists. Importantly, this is the buyer's in-country mechanism for importing a product that already holds a marketing authorisation somewhere else, for example a UK-licensed medicine. It is not a route for supplying an unlicensed product: the medicine itself is a properly authorised UK product, and the Section 21 authorisation is simply the South African regulatory route to bring it in for a defined clinical need.

Our named patient supply service describes how the UK side of this is handled.

Section 21 Named-Patient and Unregistered-Medicine Access

Section 21 of the Medicines and Related Substances Act is the legal basis on which SAHPRA can authorise access to an unregistered medicine for a particular patient or a defined clinical purpose. In practice it is South Africa's named-patient and unmet-clinical-need pathway, and it is the mechanism most hospital pharmacists and specialists use when a needed medicine has no registered local equivalent.

The application is initiated by a medical practitioner, who provides a clinical motivation setting out why the unregistered medicine is required for the patient. SAHPRA reviews the request, and once authorisation is granted the medicine can be imported and used for that purpose, dispensed under the practitioner's responsibility and within the terms of the authorisation. Records of what has been supplied are kept so the product can be traced through the supply chain.

The key point for a UK exporter and a South African buyer is one of status. The medicine supplied under a Section 21 authorisation is a properly authorised, UK-licensed product. The Section 21 permission is a feature of the buyer's South African import route, not a change in the licensed status of the medicine. Euro Biom supplies the UK-licensed product together with the country-of-origin documentation the South African importer needs to support the application.

Documentation SAHPRA Expects

For a full registration, the SAHPRA dossier follows the CTD structure and is supported by a set of country-of-origin certificates and GMP evidence, submitted through a South African applicant. The table below sets out the core documents a UK-licensed product will typically need, and who issues each one.

Two practical points sit behind that table.

Legalisation and translation. Documents issued abroad generally have to be legalised, and where translations are required they must be prepared by an authorised translator and notarised. English is an official language in South Africa, which simplifies matters for UK documentation, but the legalisation of certificates still needs to be built in early, because it is a common and avoidable source of delay.

The CPP and GMP evidence are the documents buyers underestimate. SAHPRA wants assurance that the product is genuinely approved in its country of origin and made to GMP. The CPP issued by the MHRA under the WHO certification scheme, together with current GMP evidence for the manufacturing site, is the cleanest way to provide that, and it also supports SAHPRA's reliance review. MHRA CPPs take time to obtain, so request them well ahead of a submission window. For the broader UK-side picture, see our guide to UK pharmaceutical import documentation.

Separately from the registration dossier, importing, wholesaling and distributing medicines in South Africa requires a licence under Section 22C of the Act, held by a locally established entity and supported by a Responsible Pharmacist, and a permit may be required for a given consignment. That licence sits with the buyer's South African importer or distributor, and Euro Biom supplies against it from the UK side.

How UK-Licensed Supply Fits the SAHPRA Pathway

There is a structural reason UK-licensed product travels well into South Africa. SAHPRA is looking for assurance that a medicine is properly authorised, manufactured to GMP, and traceable batch by batch. A UK-licensed, MHRA-authorised finished medicine arrives with exactly that evidence already in place: a marketing authorisation, a manufacturer operating under MHRA GMP oversight, a CPP available from the MHRA, and Qualified Person batch release with a Certificate of Analysis per batch. Because SAHPRA uses the CTD format and operates reliance pathways that recognise stringent-authority assessments, the UK paperwork does not have to be reconstructed for the South African system, it has to be assembled, legalised where required, and presented.

It is worth being precise about what UK-licensed supply means here. It means finished medicines that hold a UK marketing authorisation and are released to the UK market, not unlicensed specials. Across every route, full registration or Section 21 access, the product Euro Biom supplies is a UK-licensed, MHRA-authorised medicine. The Section 21 authorisation is a feature of the South African buyer's import route, not a change in the licensed status of the product.

Cold Chain and GDP for the South Africa Lane

A meaningful share of the specialty medicines that move from the UK to South Africa are temperature sensitive. Where that is the case, Good Distribution Practice and validated cold chain are part of what keeps the consignment compliant and the product usable on arrival. The controls that matter on this lane are:

• Validated temperature-controlled storage in the UK at the labelled storage condition before despatch.
• Qualified shipping containers appropriate to the route and to the ambient profile expected on the journey to OR Tambo in Johannesburg or to Cape Town, including the warmer months of the South African summer.
• Continuous temperature monitoring with a calibrated data logger accompanying the consignment, so the temperature history can be reviewed on arrival.
• A GDP-compliant transport chain from the UK warehouse, through air freight, to the South African importer or hospital, with a documented procedure for handling any temperature excursion.

Heathrow proximity makes the UK an efficient origin for this lane, with direct air links to Johannesburg and short despatch times for urgent cases. For more, see our UK cold chain pharmaceutical supply page and the pharma cold chain logistics guide.

Common Pitfalls and How to Avoid Them

The same handful of issues account for most delays on South Africa-bound supply. Each is straightforward to design out at the start.

1. Treating legalisation as an afterthought

Certificates that are not properly legalised, or translations that are not notarised, will not be accepted. This is procedural rather than scientific, but it stops a submission cold. Map the legalisation chain for every certificate before you start.

2. Underestimating the GMP gate

GMP assessment of the manufacturing site is central to SAHPRA approval and can affect the timeline significantly. Confirm the current GMP status and documentation for the exact manufacturing site early, and align it with the dossier rather than treating it as a late addition.

3. An out-of-date or wrong-format CPP

The CPP must genuinely confirm the UK-licensed status of the specific product and site, and it has a shelf life of its own. Request it early and check that it names the correct manufacturing site and approved particulars.

4. Confusing the two routes

Pushing an individual patient case through the full registration machinery, or assuming a Section 21 authorisation substitutes for registration in routine supply, both waste time. Match the route to the clinical and commercial reality up front.

5. Overlooking the import licence and Responsible Pharmacist

The Section 22C licence and the Responsible Pharmacist behind it are what allow the consignment to be received and distributed in South Africa. Confirm the buyer's licensing position before despatch, not on arrival.

6. Cold chain without a deviation procedure

A validated shipment can still see an excursion. Without an agreed deviation-handling procedure between supplier and consignee, an excursion can leave a consignment in limbo. Agree the procedure before the first shipment.

How Euro Biom Supports Buyers in South Africa

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines and operate the UK leg of a SAHPRA-compliant import, working with hospital pharmacies, private hospital groups, National and provincial Department of Health buyers, NGOs and licensed South African distributors and their local applicants. Across the SAHPRA pathway, our role typically covers:

• UK-side documentation. Coordinating the MHRA Certificate of Pharmaceutical Product and GMP evidence with the manufacturer or marketing authorisation holder, and assembling the GDP export pack: batch release certificate, Certificate of Analysis, packing list and commercial invoice.
• Section 21 supply. Supplying the UK-licensed product, with the country-of-origin documentation the South African importer needs to support a Section 21 application for an individual patient or cohort.
• Cold-chain logistics. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and despatch from near Heathrow to South Africa.
• Shortage and urgent supply. Rapid response on UK-licensed lines where Heathrow proximity and same-week despatch are decisive.

For more, see our UK pharmaceutical supplier to South Africa page, our guide to UK pharmaceutical import documentation, and an overview of our services.